UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~February~~March 220, 2012

NOVADEL PHARMA INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-32177	22-2407152
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(I.R.S. Employer Identification No.)
(State or other jurisdiction	(Commission File No.)	(I.R.S. Employer
of incorporation or organization)		Identification No.)

1200 ~~Route~~ Route 22 East, Suite 2000 Bridgewater, NJ 08807 (Address of principal executive offices) (Zip Code)

(908) 203-4640
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 12.0102. ~~Entry~~Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition.

On ~~February~~March 220, 2012, NovaDel Pharma Inc., a Delaware corporation (the “Company”), ~~entered~~issued ~~into~~ a ~~binding~~press ~~term~~release ~~sheet with Apricus Biosciences, Inc. (“Apricus”) whereby the~~to ~~Company~~report ~~has~~its ~~agreed~~unaudited tofinancial ~~(i)~~results ~~sell~~for ~~to Apricus certain intellectual property rights relating to~~ the ~~Company’s~~quarter ~~nitroglycerin lingual spray~~ and ~~(ii)~~year ~~grant~~ended ~~Apricus a~~December ~~perpetual exclusive royalty-free license to commercialize the Company’s nitroglycerin lingual spray~~31, in2011. ~~each~~A ~~case~~copy ~~for all countries, territories and possessions~~ of the ~~world~~press ~~outside~~release ofis ~~the~~furnished ~~United~~pursuant ~~States~~to ~~and~~this ~~its~~Item ~~possessions,~~2.02 ~~territories~~as ~~and~~Exhibit ~~commonwealths,~~99.1 ~~Canada~~to ~~and~~this ~~Mexico~~Current ~~(collectively,~~Report ~~the “Transaction”).~~on Form 8-K.

~~The~~This ~~Company and~~Current ~~Apricus~~Report ~~intend~~on toForm 8-K, ~~enter~~as ~~into~~it arelates ~~definitive~~to ~~asset~~Item ~~sale~~2.02, ~~and~~is ~~license~~being ~~agreement to~~furnished ~~memorialize~~pursuant ~~the~~to ~~terms~~Item of2.02 and the ~~Transaction~~press ~~set~~release ~~forth~~is inbeing ~~the~~furnished ~~Term~~pursuant ~~Sheet~~to onItem ~~or before February~~ 9~~, 2012~~.01 Asof ~~consideration~~this ~~for~~Current Report ~~entering~~on ~~into~~Form ~~the~~8-K ~~asset sale~~ and ~~license~~ ~~agreement,~~shall ~~Apricus~~not ~~will~~be ~~pay~~deemed ~~the~~“filed” ~~Company~~for anpurposes ~~amount~~of ~~equal~~Section ~~to $200,000. In~~18 ~~the~~of ~~event~~ the ~~parties~~Securities ~~fail~~Exchange toAct ~~enter~~of ~~into~~1934, aas ~~definitive~~amended ~~asset~~(the ~~sale~~“Exchange ~~and~~Act”), ~~license~~or ~~agreement~~otherwise bysubject ~~February~~to ~~9, 2012,~~ the ~~terms~~liabilities ~~and conditions~~ of ~~the~~that ~~Term~~Section, ~~Sheet~~nor shall ~~govern~~ ~~the~~it ~~Transaction~~be ~~and~~deemed incorporated ~~the~~by ~~Transaction~~reference ~~shall~~in ~~close~~any ~~pursuant~~filing tounder the ~~terms~~Securities Act of ~~the~~ ~~Term~~1933, ~~Sheet~~as amended, onor ~~February~~the ~~10,~~Exchange ~~2012~~Act.

A complete copy of the Term Sheet is attached to this Form 8-K. The foregoing description of the Term Sheet is qualified in its entirety by reference to such document.


Item 9.01	Financial Statements and Exhibits.

	(d)	Exhibits

	Exhibit No.	Description


	99.1	Press Release of NovaDel Pharma Inc. dated March 20, 2012, titled “NovaDel Reports Unaudited Financial Results for Fourth Quarter and Year Ended December 31, 2011.”

Item 9.01 Financial Statements and Exhibits.

	(d)		Exhibits
	Exhibit No.		Description
	10.1		Term Sheet, dated February 2, 2012, by and between the Company and Apricus Biosciences, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	NovaDel Pharma Inc.

	By:	/s/ STEVEN B. RATOFF

	Name:	Steven B. Ratoff
	Title:	President, Chief Executive Officer and Interim Chief Financial Officer

Date: ~~February~~March 821, 2012

Filing Compare · NOVADEL PHARMA INC